RxDoctor Payments Data

Susan McKelvey

Family · Ithaca, NYNPI 1669760682

Payments from drug & device makers

$3,887in general payments, 2019–2025

Across 167 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$232
  • Pfizer$208
  • Eisai Inc.$197
  • UCB, Inc.$184
  • Biohaven Pharmaceuticals, Inc.$177
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,85199%
  • Other$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,887 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$47,343
Medicare patients
237
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe48$39,090
Nurtec OdtRimegepant Sulfate35$35,929
Emgality SyringeGalcanezumab-Gnlm11$23,041
UbrelvyUbrogepant24$21,816
Emgality PenGalcanezumab-Gnlm21$15,885
Ajovy AutoinjectorFremanezumab-Vfrm23$15,488
QuliptaAtogepant12$11,859
Levetiracetam91$6,008
Carbamazepine ErCarbamazepine25$4,980
Memantine Hcl128$4,440
Carbidopa-LevodopaCarbidopa/Levodopa76$3,576
Pregabalin122$3,325
Divalproex Sodium ErDivalproex Sodium15$2,988
Gabapentin213$2,864
Carbidopa-Levodopa ErCarbidopa/Levodopa57$1,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$208$35,92935 claims
AbbVieUbrelvy, Qulipta$1,530$33,67536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →